The Commercial Receivers Association (CRA), a national membership organization focused on empowering the education and standardization of Commercial Receivership Administration, is expanding its reach to include Indiana and Oregon.

The assets of American Titanium Works LLC will be sold in a UCC Article 9 sale on May 2nd, 2024 at 11:00 am PT. Professionals Involved: Joseph C. Barsalona II, Esq. of Pashman Stein Walder Hayden, P.C., Counsel to Tronox LLC and Brian Testo of Brian Testo Associates, LLC, Auctioneer.

The assets of CHOL ENTERPRISES INC. will be sold in a UCC Article 9 sale on May 15, 2024 at 11:00 am PT. Professionals Involved: Brian Testo of
Brian Testo Associates, LLC, Auctioneer

The assets of Sky Capital Group LLC d/b/a Roady’s Truck Stops will be sold in a UCC Article 9 sale. Professionals Involved: Jacob Sparks, Esq. of Nelson Mullins Riley & Scarborough LLP

Metavine Inc. filed for Chapter 11 bankruptcy on January 3, 2024 in the U.S. Bankruptcy Court for the Central District of California. Metavine Inc. is the developer of Crowd Machine, an enterprise-grade, no-code platform that enables continuous digital evolution by driving collaborative partnership between the IT department and the business user. The platform Integrates applications and microservices with legacy systems, builds new applications faster and easier with no-code, and delivers speed, security, sophistication, and digital agility like no other platform can. Bids must be submitted by April 19, 2024 at 5:00 pm PT. The auction will be held at 11:00 am PT on April 23, 2024. Professionals Involved: Jonathan Wernick of B.Riley Advisory Services

The assets of Ribon Therapeutics Inc. will be sold in a UCC Article 9 sale on May 9th at 12:00 pm ET via online videoconference. Ribon Therapeutics Inc. is a clinical stage biopharmaceutical company involved in the development of novel small molecules targeting stress support pathways in cancer and inflammation using a proprietary platform technology. The company has discontinued all material operations as of the date hereof. The Sale Assets consist primarily of intellectual property registered in the name of Debtor and other assets related to Debtor’s product candidate, RBN-2397 (PARP7 inhibitor), RBN-3143 (PARP14 inhibitor) and preclinical follow-on program (including PARP14 degrader), and Debtor’s interest in certain deferred and contingent milestone payments owed to Debtor by Boehringer Ingelheim pursuant to an existing asset sale transaction of the CD38 program (a preclinical asset). Interested parties must submit their bid and a proposed asset purchase agreement together with a deposit in accordance with the bid procedures, and provide other qualifying information such as proof of ability to fund the purchase no later than Friday May 3rd at 5 p.m. ET. Professionals Involved: Heidi Lipton of Rock Creek Advisors

The Commercial Receivers Association Prepares to Celebrate its Second Annual Conference in Palm Beach, FL August 18-21, 2024

90 Second Lesson: Are Secured Creditors Better Off With a Federal Court Receivership or Bankruptcy?

What benefits creditors more? When considering federal court receivership vs. bankruptcy, bankruptcy is often more predictable, but costly.

OCHO Candy is an organic fair trade chocolate confection manufacturer. The company ceased business operations and entered into an Assignment for the Benefit of Creditors on February 8, 2024. The Assignee is now soliciting bids for the acquisition of OCHO Candy’s portfolio of intellectual property. All interested parties wishing to make competitive offers for the Assets must submit a qualified bid to the Assignee for the Benefit of Creditors no later than April 19, 2024, at 5:00 om CT. Professionals Involved: Tom Frey and Matthew Sorenson of DSI Consulting.

Civetta Therapeutics is a pioneering bio-tech research firm focused on exploiting the therapeutic potential of β-propeller proteins. Civetta ceased business operations and entered into an Assignment for the Benefit of Creditors on December 22, 2023. The Assignee is now soliciting bids for the acquisition of Civetta Therapeutics’ extensive portfolio of intellectual property, a treasure trove of groundbreaking research and innovation in the field of biotechnology. The available intellectual property portfolio encompasses research by Civetta in a niche area of biotechnology, offering a unique opportunity for entities interested in this field to acquire a comprehensive portfolio of intellectual property with vast therapeutic and commercial potential. Offers must be made no later than April 30, 2024, at 5:00 pm CT. Professionals Involved: William G. Brandt and Matthew Sorenson of DSI Consulting.